OneMedNet Corporation (ONMD) is a Minneapolis-based healthcare data company that operates the iRWD platform, de-identifying and curating medical imaging and clinical records into regulatory-grade real-world datasets sold to life sciences companies, device makers, and AI developers. Its network spans more than 2,300 provider sites and roughly 90 million patient journeys.
In Thursday's session, the stock climbed 5.84% to $4.71, up $0.26 from Wednesday's close of $4.45, with the shares trading higher within the first hour of the regular session. The direction was unambiguously positive. No verified news or fundamental development was published before the open to explain the advance; the move instead fits a pattern of sharp, low-volume swings that have defined this micro-cap's trading history.
No verified news or fundamental catalyst found for today's gain. No press release, 8-K, financing, analyst rating change, or partnership announcement appeared on November 19 ahead of the price action, and nothing material surfaced in the prior evening.
The most plausible explanation is technical and liquidity-driven. ONMD closed at $4.45 on November 18 after a 9.74% slide, a drop that itself had no accompanying disclosure and took the shares to their lowest close since early November. A rebound of this kind is consistent with short-covering and opportunistic buying in a name where a single modest order can shift the quote several percent. The evidence is in the tape: over the last 60 completed sessions the stock's average absolute daily move has been roughly 5.2%, and 18 of those sessions produced a move equal to or larger than today's 5.84%. Today's swing is only about 1.1 times the stock's typical daily range — a routine fluctuation for this security rather than an outlier.
Fundamentally, the backdrop investors are still working with is the third-quarter report published on November 17. Revenue for the quarter reached $1.02 million, up 250% sequentially and 478% from a year earlier, while management reaffirmed fourth-quarter revenue guidance of approximately $12 million to $14 million, contingent on customers accepting delivered data before quarter-end. Year-to-date contracted bookings of roughly $18.76 million dwarf 2025's full-year total, but the conversion rate into reported revenue is still modest, which is why the results themselves did not sustain a rally.
Volume was light in early trading relative to an already thin float, reinforcing the view that the move reflects a shallow order book rather than a change in institutional positioning. The stock has repeatedly posted double-digit percentage swings on only a few thousand shares traded, and today's activity has so far followed that script.
There was no sector-wide or index-level event driving the change. OneMedNet's move diverged from broad large-cap benchmarks and from the wider real-world-data and healthcare-AI group, which traded without a shared catalyst. Technically, the shares are bouncing from the $4.45 area but remain well below the $6.00 close reached on November 9 and far under the 52-week high of $23.00, so the advance has not broken any meaningful resistance and reads as a reflex rally inside a months-long downtrend.
The score runs from 0 to 100, where 0 means no meaningful news combined with a move that is entirely normal for the stock, and 100 means transformative news paired with an extreme, once-in-years price swing. ONMD scores 11 out of 100.
The news component is weak. No verified catalyst was published for today's session, so only the residual effect of the November 17 quarterly report carries any weight, and that report largely restated figures already disclosed on November 6. The price component is equally unremarkable: today's 5.84% gain is about 1.1 times the stock's typical daily move, and moves of that size or larger occurred 18 times in the last 60 sessions. Two weak components combine into a low score.
The decisive variable is fourth-quarter revenue. Management has guided to roughly $12 million to $14 million, a figure that depends on customers formally accepting delivered datasets before the quarter closes, so any timing slip would push recognition into 2027. Investors will also want the 10-Q detail on margins and cash burn, which the earnings releases did not disclose, along with updates on the company's growing roster of channel partners and its progress converting the $18.76 million bookings backlog into billings.
Risks cut both ways. On the upside, a clean fourth-quarter delivery would validate the scale-up story and mark a step change in revenue. On the downside, dilution risk is real for a company of this size with a loss-making profile, and the float remains small enough that both rallies and selloffs can overshoot. Absent fresh disclosures, expect the shares to stay sensitive to order flow rather than headlines.
Tickeron's Trending AI Robots page offers a curated window into automated trading. The platform runs hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are surfaced in this section. Bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the list changes as market conditions shift. It is a practical starting point for investors who want to see which systematic approaches are working right now — worth a look before the next session.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ONMD moved below its 50-day moving average on November 11, 2026 date and that indicates a change from an upward trend to a downward trend. In 31 of 34 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ONMD as a result. In 45 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ONMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ONMD broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ONMD's RSI Oscillator exited the oversold zone, 17 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for ONMD just turned positive on October 21, 2026. Looking at past instances where ONMD's MACD turned positive, the stock continued to rise in 34 of 56 cases over the following month. The odds of a continued upward trend are 61%.
Following a +43.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where ONMD advanced for three days, in 113 of 149 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 54 of 233 cases where ONMD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 23%.
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. ONMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ONMD's P/B Ratio (-86.621) is very low in comparison to the industry average of (4.523). P/E Ratio (-3.024) is within average values for comparable stocks, (12.601). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. ONMD's P/S Ratio (23.529) is slightly higher than the industry average of (6.105).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry ServicestotheHealthIndustry